However, the results from our study suggest that routine testing for aβ2GPI and aCL at 12 weeks for young CIS patients could be necessary despite the initially negative results from the acute phase, in order to consider appropriately targeted secondary prevention. This evidence concerns the gene ACLY and in situ carcinoma.